Paulina Lugo रीट्वीट किया
Breast cancer is entering a chemo-free, ADC-driven, ctDNA-guided era.
ESMO Breast 2026 could quietly redefine practice.
Here are 10 trials you should NOT miss 👇
1️⃣ PHERGain-2
🧬 Early HER2+
👉 Chemo-free dual HER2 blockade strategy
🎯 Can we safely omit chemo?
2️⃣ TRAIN-4
🧬 Early HER2+
👉 Anthracycline-free ± escalation
🎯 Is less more?
3️⃣ DESTINY-Breast11
🧬 Neoadjuvant HER2+
👉 Trastuzumab deruxtecan vs standard
🎯 ADC replacing chemo?
4️⃣ HER2CLIMB-02
🧬 HER2+ metastatic
👉 Tucatinib + Trastuzumab emtansine
🎯 Brain mets control
5️⃣ SATEEN
🧬 Post-Trastuzumab deruxtecan setting
👉 Sequencing strategies
🎯 What after T-DXd?
6️⃣ TROPION-Breast04
🧬 HR+/HER2- metastatic
👉 Datopotamab deruxtecan
🎯 Next ADC wave
7️⃣ DESTINY-Breast06 (updates)
🧬 HER2-low / ultra-low
👉 Expanding Trastuzumab deruxtecan
🎯 Redefining HER2 biology
8️⃣ PERSEVERE
🧬 ctDNA-guided early BC
👉 MRD-based escalation/de-escalation
🎯 Precision adjuvant therapy
9️⃣ lidERA (Giredestrant)
🧬 Early ER+
👉 Giredestrant vs standard ET
🎯 SERDs moving early
🔟 CAMBRIA-2
🧬 ER+ high-risk
👉 Camizestrant
🎯 Endocrine backbone changing?
#OncoTwitter #MedTwitter #BreastCancer #ADC
@myESMO @ESMO_Open @stolaney1 @OncoAlert @OncBrothers @Larvol
English
